Cohance Lifesciences approves acquisition of 26% stake in solar power generating entity

The board of Cohance Lifesciences at its meeting held on 06 November 2026 has approved proposed equity investment of 26% in the SPV (under incorporation) to be engaged in solar power generation for the purpose of captive consumption of the company`s plant operation.